Mirae Asset Global Investments Co. Ltd. Sells 74,818 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Mirae Asset Global Investments Co. Ltd. lowered its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 85.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,721 shares of the company's stock after selling 74,818 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Recursion Pharmaceuticals were worth $94,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals in the third quarter worth approximately $25,000. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the fourth quarter worth approximately $26,000. GAMMA Investing LLC boosted its holdings in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after acquiring an additional 4,091 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after purchasing an additional 3,377 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of recent research reports. Needham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded up $0.30 during mid-day trading on Tuesday, reaching $10.83. 53,314,286 shares of the company's stock were exchanged, compared to its average volume of 23,578,424. The business's fifty day simple moving average is $7.32 and its 200 day simple moving average is $6.93. The firm has a market capitalization of $4.23 billion, a PE ratio of -7.08 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a one year low of $5.60 and a one year high of $15.74. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.